This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The EVOQUE tricuspid valve replacement system is a device designed to treat patients with severe leaking of the tricuspid valve, known as tricuspid regurgitation, without openheartsurgery.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
milla1cf Mon, 06/10/2024 - 17:58 June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial tricuspid clip procedure in the Carolinas, performed in May at Atrium Health Carolinas Medical Center.
Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heartvalve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected.
“Patients with severely calcified mitral stenosis are often not candidates for conventional open-heartsurgery,” said Dr. Giustino. This minimally invasive technique pioneered at Henry Ford is a promising and safe treatment option for these patients to improve their cardiac symptoms and quality of life."
The panel's vote will be considered by the FDA when making a decision regarding the approval of TriClip, a first-of-its-kind minimally invasive device specifically designed to treat the difficult-to-access tricuspid valve. chief medical officer and divisional vice president of medical affairs of Abbott's structural heart business.
Traditionally, cardiothoracic surgeons have repaired or replaced the tricuspid valve during open-heartsurgery and only when absolutely necessary; such surgeries are complex and risky. Catheter-based procedures offer an alternative for patients who are not candidates for open-heartsurgery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content